HDAC9 and cancer: Vorinostat, a Histone Deacetylase (HDAC) inhibitor, has been demonstrated to exert anticancer effects through multiple mechanisms, including inducing cancer cell death, suppressing proliferation and modulating immune responses [41, 42].